DAVID M LIVINGSTON, M.D.
Osteopathic Medicine at Binney St, Boston, MA

7176345, Feb 13, 2007

Nov 4, 2002

10/287670

David M. Livingston - Brookline MA, US
Tae-You Kim - Seoul, KR

Dana-Farber Cancer Institute, Inc. - Boston MA

A01K 67/027, A01K 67/00, G01N 33/00

800 18, 800 3, 800 13

Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e. g. , ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.

5658784, Aug 19, 1997

Apr 14, 1994

8/227536

Richard Eckner - Boston MA
Mark Ewen - Brookline MA
David Livingston - Brookline MA

Dana-Farber Cancer Institute, Inc. - Boston MA

C07H 2104

435325

The invention features an isolated nucleic acid hybridizable with the complement of the coding strand nucleic acid sequence presented in SEQ ID NO:1, and encoding a protein that is necessary for adenovirus transformation of a mammalian cell. The encoded protein, p300, cooperates with adenovirus E1A (Early-region 1A) proteins to establish the transformed state.

5695946, Dec 9, 1997

May 3, 1995

8/433076

Thomas L. Benjamin - Cambridge MA
Joan Chen-Wu - Brookline MA
Thomsen Hansen - Brookline MA
Barbara Jackson - Roslindale MA
David Livingston - Brookline MA
Steven Tannenbaum - Framingham MA
Gerald Wogan - Belmont MA

Vicam, LP - Sommerville MA

G01N 3302, G01N 33538, G01N 33547, G01N 33569

435 732

An assay method is provided to easily and quickly detect the presence of organisms capable of being cultured, such as bacteria, characterized by antibody capture of the organism of interest by use of specialized magnetic beads, incubation of the captured cells to form colonies; removal of material from the colonies with a colony lift membrane; and detection of the colony material on the membrane sheet by use of labeled antibodies, PCR or nucleic acid probes.

5759803, Jun 2, 1998

May 13, 1992

7/882711

William G. Kaelin - Boston MA
Erik Flemington - Brookline MA
William Sellers - Brookline MA
David M. Livingston - Brookline MA

Dana-Farber Cancer Institute - Boston MA

C12N 1512, C07K 14435

435 691

We have discovered a nuclear protein in normal human cells, "retinoblastoma-associated protein 1" ("RBAP-1"), also known as E2F-1, that binds directly to the retinoblastoma protein pocket of the underphosphorylated form of the retinoblastoma protein ("RB") and does not bind to phosphorylated RB or to RB with inactivating mutations. The translated RBAP-1 sequence does not resemble other proteins whose sequences are known, and RBAP-1 does not contain a sequence homologous to the transforming element common to viral proteins that bind to the RB pocket. RBAP-1 and the E2F transcription activity have similar DNA-binding specificities and can bind to at least some of the same proteins, such as RB and E4.

7919274, Apr 5, 2011

Mar 19, 2002

10/101662

David M. Livingston - Brookline MA, US
Tae-You Kim - Seoul, KR

Dana-Farber Cancer Institute, Inc. - Boston MA

C12P 21/04

435 697, 435 698, 530356, 5303873

Light-generating fusion proteins having a ligand binding site and a light-generating polypeptide moiety and their use as diagnostics, in drug screening and discovery, and as therapeutics, are disclosed. The light-generating fusion protein has a feature where the bioluminescence of the polypeptide moiety changes upon binding of a ligand at the ligand binding site. The ligand may be, for example, an enzyme present in an environment only under certain conditions, e. g. , ubiquitin ligase in a hypoxic state, such that the light-generating fusion protein is “turned on” only under such conditions.

2003006, Apr 10, 2003

Nov 15, 2002

10/295345

Thomas Benjamin - Cambridge MA, US
Barbara Kohn - Watertown MA, US
Christopher Basker - Mansfield MA, US
Susan George - Chelmsford MA, US
David Livingston - Brookline MA, US

Vicam, L.P. - Watertown MA

G01N033/53, G01N033/567, A01K031/19

435/007200, 800/021000, 119/300000

A method for increasing the percentage of mammalian offspring of either sex which comprises contacting a semen sample with an antibody specific for the spermatozoa determinative of one sex and separating said spermatozoa from spermatozoa determinative of the other sex, said antibody being bound to a non-porous magnetic bead support having a diameter of 0.1 to 2 microns.

5981723, Nov 9, 1999

Jun 5, 1995

8/462174

William G. Kaelin - Boston MA
Erik Flemington - Brookline MA
James A. DeCaprio - Wellesley MA
William Sellers - Brookline MA
David M. Livingston - Brookline MA

Dana-Farber Cancer Institute - Boston MA

C12N 1512

536 235

We have discovered a nuclear protein in normal human cells, "retinoblastoma-associated protein 1" ("RBAP-1") that binds directly to the retinoblastoma protein pocket of the underphosphorylated form of the retinoblastoma protein ("RB") and does not bind to phosphorylated RB or to RB with inactivating mutations. The translated RBAP-1 sequence does not resemble other proteins whose sequences are known, and RBAP-1 does not contain a sequence homologous to the transforming element common to viral proteins that bind to the RB pocket. RBAP-1 and the E2F transcription activity have similar DNA-binding specificities and can bind to at least some of the same proteins, such as RB and E4.

8486648, Jul 16, 2013

Feb 16, 2006

11/883103

David Livingston - Brookline MA, US
Ronny Drapkin - Newton MA, US

Dana-Farber Cancer Institute, Inc. - Boston MA

C12Q 1/00, G01N 1/00, G01N 21/00, G01N 21/75, G01N 33/00, G01N 33/48, G01N 33/53, G01N 33/567, G01N 33/574

435 723, 435 4, 435 71, 435 721, 435 772, 435 792, 436 63, 436 64, 436164, 436166, 436174, 436501

The present invention provides methods of detecting ovarian cancer using biomarkers.

7732658, Jun 8, 2010

Jul 10, 2008

12/218042

David M. Livingston - Brookline MA, US
Andrew L. Kung - Walpole MA, US

Dana Farber Cancer Institute, Inc. - Boston MA

A01K 67/027, C12N 15/00, G01N 33/00

800 18, 800 25, 800 3

The invention relates to compositions containing a polynucleotide encoding for a reporter gene, a selectable marker and a regulatory element, that provide a method for imaging cells in vivo.